

Supplementary Materials: Intramedullary Spinal Cord Tumors: Whole Genome Sequencing to Assist Management and Prognosis

Miguel Mayol del Valle ^{1,*}, Bryan Morales ², Brandon Philbrick ³, Segun Adeagbo ³, Subir Goyal ⁴, Sarah Newman ¹, Natasha L. Frontera ⁵, Edjah Nduom ¹, Jeffrey Olson ¹, Stewart Neill ² and Kimberly Hoang ¹

¹ Emory University Hospital, Department of Neurosurgery, 1365 Clifton Road NE, Suite B6200, Atlanta, GA 30322 USA

² Emory University Hospital, Department of Neuropathology, 1364 Clifton Road, NE Room H-184, Atlanta, GA 30322 USA

³ Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA 30322 USA

⁴ Biostatistics Shared Resource Department, Winship Cancer Institute of Emory University, 1365-C Clifton Road, NE, Atlanta, GA 30322 USA

⁵ University of Puerto Rico Medical Sciences Campus, School of Medicine, PO Box 365067, San Juan, PR 00936-5067

* Correspondence: mmayold@emory.edu

Table S1. (Patients with genetic testing).

| Age | Sex | BMI | Comorb | Location | Resect % | PO KPS | Hosp (days) | Diagnosis | Important Mutations | Gain | Loss | LOH | Total | Radiation (Dose) | Chemo | Progre | Follow-up (Days) |
|-----|--------|------|--------------|-------------|----------|--------|-------------|-----------------------------------|--|------|------|-----|-------|----------------------------|---------|---------------|------------------|
| 68 | Female | 21.9 | HTN | Thoracic | 100% | 60 | 9 | LGA (WHO II) | IDH WT | n/a | n/a | n/a | n/a | | | | 8 |
| 70 | Female | 26.9 | DM | Cervical | 78-99% | 40 | 16 | Ependymoma (WHO II) | IDH WT | n/a | n/a | n/a | n/a | | | YES-Surgery | 754 |
| 38 | Male | 18 | | Thoracic | Biopsy | 50 | 8 | LGA (WHO II) | IDH WT, BRAFV600E | n/a | n/a | n/a | n/a | Fractionated (50.4) | | | 303 |
| 37 | Female | 22.3 | | Cervical | 100% | 90 | 5 | Ependymoma (WHO II) | IDH WT | n/a | n/a | n/a | n/a | | | | 36 |
| 71 | Female | 44.4 | HTN, CAD, DM | Thoracic | 0% | 60 | 8 | Astrocytoma (WHO III) | IDH WT, P53 overexp | n/a | n/a | n/a | n/a | Fractionated (50.4) | | YES-Radiation | 223 |
| 47 | Female | 38.1 | | Cervical | 100% | 80 | 4 | LGA (WHO II) | | n/a | n/a | n/a | n/a | | | | 359 |
| 61 | Female | 22.5 | | Cervicothor | 78-99% | 40 | 13 | Ependymoma (WHO II) | | 0 | 2 | 0 | 2 | | | | 107 |
| 55 | Female | 28.3 | | Cervical | 78-99% | 60 | 7 | Ependymoma (WHO II) | | 0 | 2 | 0 | 2 | Fractionated Proton (50.4) | | | 610 |
| 54 | Male | 28.3 | | Cervical | Biopsy | 80 | 3 | Ependymoma (WHO II) | IDH WT | 5 | 3 | 0 | 8 | Fractionated Proton (52.2) | | | 467 |
| 61 | Male | 28.2 | HTN, MI | Cervical | 78-99% | 60 | 21 | Ependymoma (WHO II) | | 2 | 6 | 1 | 9 | | | Yes-Death | 43 |
| 29 | Male | 34.3 | HTN, DM | Thoracic | 78-99% | 80 | 4 | Glioblastoma (WHO IV)) | IDH WT, ATRX Del, MGMT Meth, KRAS pos | 6 | 6 | 1 | 13 | Fractionated (48.6) | Temodar | YES-Chemo/Rad | 143 |
| 68 | Female | 24.9 | | Lumbar | 100% | 80 | 5 | Myxopapillary Ependymoma (WHO II) | | 6 | 10 | 0 | 16 | | | | 536 |
| 41 | Female | 38.3 | HTN, CAD | Cervical | <50% | 70 | 11 | Glioblastoma (WHO IV)) | IDH WT, ATRX Del, MGMT Meth, P53 overexp | 0 | 25 | 5 | 30 | | | Yes-Hospice | 39 |
| 54 | Male | 23.5 | | Cervical | 100% | 90 | 6 | Ependymoma (WHO II) | | 37 | 0 | 0 | 37 | | | | 161 |